You are here

  • Home
  • Archive
  • Volume 65, Issue 12
  • Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

Article metrics

Article menu

See original article:

Download PDFPDF

Correction
Erratum: Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
Free

 

Online download statistics by month:

Online download statistics by month: November 2016 to March 2024

AbstractFullPdf
Nov 20166086650
Dec 201622643391
Jan 2017621514
Feb 201783746
Mar 201724013
Apr 201703718
May 20170315
Jun 2017133413
Jul 201723203
Aug 201740369
Sep 2017343111
Oct 201731316
Nov 201725258
Dec 201716162
Jan 201827194
Feb 201814142
Mar 201819177
Apr 201830292
May 201819191
Jun 201831281
Jul 201816142
Aug 201817134
Sep 201812122
Oct 2018550
Nov 2018661
Dec 2018882
Jan 201911112
Feb 2019551
Mar 2019665
Apr 2019776
May 2019774
Jun 2019993
Jul 201913135
Aug 2019553
Sep 2019992
Oct 2019997
Nov 201913135
Dec 2019330
Jan 2020993
Feb 202016153
Mar 2020883
Apr 2020112
May 2020445
Jun 2020222
Jul 202010103
Aug 2020001
Sep 202012121
Oct 202012122
Nov 2020883
Dec 202012124
Jan 2021651
Feb 2021223
Mar 2021333
Apr 2021544
May 2021333
Jun 202125252
Jul 202111104
Aug 2021111
Sep 2021665
Oct 20216516
Nov 20213310
Dec 2021554
Jan 2022777
Feb 2022331
Mar 20221092
Apr 2022334
May 202218185
Jun 202219173
Jul 2022781
Aug 202219194
Sep 202221206
Oct 202227276
Nov 2022772
Dec 2022531
Jan 2023762
Feb 202337372
Mar 2023320
Apr 2023331
May 2023113
Jul 2023117
Aug 2023655
Sep 2023440
Oct 2023873
Nov 2023661
Dec 202315131
Jan 2024773
Feb 2024434
Mar 20242111
Total18091145833